Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Adenocarcinoma
/ diagnostic imaging
Animals
Antigens, Neoplasm
/ immunology
CD11b Antigen
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Colorectal Neoplasms
/ diagnostic imaging
Female
Mice
Neoplasm Proteins
/ immunology
Neoplasms, Experimental
/ diagnostic imaging
Positron-Emission Tomography
Programmed Cell Death 1 Receptor
/ immunology
Tumor Microenvironment
/ immunology
PET imaging
checkpoint blockade
nanobodies
single-cell RNA sequencing
tumor immune microenvironment
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
20 08 2019
20 08 2019
Historique:
pubmed:
4
8
2019
medline:
24
3
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive results in a wide range of cancers. However, the response remains heterogeneous among patients. We used noninvasive immuno-positron emission tomography (PET), using
Identifiants
pubmed: 31375632
pii: 1905005116
doi: 10.1073/pnas.1905005116
pmc: PMC6708368
doi:
Substances chimiques
Antigens, Neoplasm
0
CD11b Antigen
0
Itgam protein, mouse
0
Neoplasm Proteins
0
Pdcd1 protein, mouse
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16971-16980Subventions
Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI087879
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI056299
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA080111
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA226040
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA207021
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Scand J Immunol. 2001 Apr;53(4):386-92
pubmed: 11285119
J Virol. 2003 Apr;77(7):4004-14
pubmed: 12634360
Nat Genet. 2004 Sep;36(9):952-4
pubmed: 15322544
Blood. 2005 Aug 15;106(4):1314-22
pubmed: 15870184
J Immunol. 2005 Dec 15;175(12):8200-8
pubmed: 16339559
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Curr Opin Immunol. 2007 Jun;19(3):309-14
pubmed: 17433872
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
Cancer Immunol Immunother. 2010 Oct;59(10):1543-9
pubmed: 20567822
J Clin Invest. 2011 Oct;121(10):4015-29
pubmed: 21911941
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
PLoS One. 2013 Aug 14;8(8):e71207
pubmed: 23967166
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
J Immunother Cancer. 2014 Feb 18;2:3
pubmed: 24829760
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Genome Biol. 2014;15(12):550
pubmed: 25516281
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6146-51
pubmed: 25902531
Cancer Res. 2016 Jan 1;76(1):73-82
pubmed: 26573799
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):528-533
pubmed: 26630549
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
ACS Cent Sci. 2015 Jun 24;1(3):142-147
pubmed: 26955657
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Clin Transl Immunology. 2016 Nov 02;5(11):e111
pubmed: 27990286
For Immunopathol Dis Therap. 2015;6(1-2):7-17
pubmed: 28286692
Cancer Res. 2017 Aug 1;77(15):3982-3989
pubmed: 28428275
Mol Oncol. 2017 Jul;11(7):824-846
pubmed: 28614624
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Exp Cell Res. 2017 Oct 15;359(2):449-457
pubmed: 28830685
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
Oncogenesis. 2018 Mar 29;7(3):32
pubmed: 29593211
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Lab Chip. 2018 Oct 9;18(20):3129-3143
pubmed: 30183789
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Nature. 1988 Aug 4;334(6181):395-402
pubmed: 3043226
Cell. 1984 Jun;37(2):393-401
pubmed: 6202421